LIGAND PHARMACEUTICALS INC 8-K

What Happened

• On February 26, 2026, Ligand Pharmaceuticals Incorporated announced its financial results for the three months and twelve months ended December 31, 2025 by issuing a press release. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition).
• The filing notes the press release is furnished under General Instruction B.2 of Form 8-K and therefore is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Reporting periods: three months and twelve months ended December 31, 2025 (Q4 and full year 2025).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form signed on behalf of the company by Andrew Reardon, Chief Legal Officer and Secretary.

Why It Matters

• This 8-K signals that Ligand has publicly released its quarterly and annual financial results; investors should read the press release (Exhibit 99.1) for revenue, earnings, guidance, and other performance metrics that could affect the stock.
• The legal note that the release is “furnished” (not “filed”) limits certain liabilities under Section 18, which is a disclosure formality investors may want to be aware of when relying on this release.